Skip to Content

Pentostatin Dosage

Applies to the following strengths: 10 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Hairy Cell Leukemia

For use as single agent treatment for both untreated and alpha interferon refractory hairy cell leukemia patients with active disease (as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease related symptoms):
4 mg/m2 every other week. (Higher doses are not recommended.)

Renal Dose Adjustments

There are insufficient data to recommend a starting or a subsequent dose for patients with impaired renal function (creatinine clearance <60 mL/min)

Liver Dose Adjustments

Data not available.


-This drug should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. The use of higher doses than those specified is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in studies that used higher doses (20 to 50 mg/m2 in divided doses over 5 days) than recommended.
-In a clinical investigation in patients with refractory chronic lymphocytic leukemia taking this drug at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. This drug should not be used in combination with fludarabine phosphate.

Consult WARNINGS section for additional precautions.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available.

Other Comments

It is recommended that patients receive hydration with 500 to 1,000 mL of 5% dextrose in 0.5 normal saline or equivalent before pentostatin administration. An additional 500 mL of 5% dextrose or equivalent should be administered after pentostatin is given.

The optimal duration of treatment has not been determined. In the absence of major toxicity and with observed continuing improvement, the patient should be treated until a complete response has been achieved. Although not a requirement, the administration of two additional doses has been recommended following the achievement of a complete response.